215 related articles for article (PubMed ID: 24342436)
1. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
[TBL] [Abstract][Full Text] [Related]
2. The fibromatosis signature defines a robust stromal response in breast carcinoma.
Beck AH; Espinosa I; Gilks CB; van de Rijn M; West RB
Lab Invest; 2008 Jun; 88(6):591-601. PubMed ID: 18414401
[TBL] [Abstract][Full Text] [Related]
3. Stromal responses among common carcinomas correlated with clinicopathologic features.
Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
[TBL] [Abstract][Full Text] [Related]
4. Determination of stromal signatures in breast carcinoma.
West RB; Nuyten DS; Subramanian S; Nielsen TO; Corless CL; Rubin BP; Montgomery K; Zhu S; Patel R; Hernandez-Boussard T; Goldblum JR; Brown PO; van de Vijver M; van de Rijn M
PLoS Biol; 2005 Jun; 3(6):e187. PubMed ID: 15869330
[TBL] [Abstract][Full Text] [Related]
5. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
6. Variations in stromal signatures in breast and colorectal cancer metastases.
Webster JA; Beck AH; Sharma M; Espinosa I; Weigelt B; Schreuder M; Montgomery KD; Jensen KC; van de Rijn M; West R
J Pathol; 2010 Oct; 222(2):158-65. PubMed ID: 20593409
[TBL] [Abstract][Full Text] [Related]
7. Stromal signatures in endometrioid endometrial carcinomas.
Espinosa I; Catasus L; D' Angelo E; Mozos A; Pedrola N; Bértolo C; Ferrer I; Zannoni GF; West RB; van de Rijn M; Matias-Guiu X; Prat J
Mod Pathol; 2014 Apr; 27(4):631-9. PubMed ID: 24263966
[TBL] [Abstract][Full Text] [Related]
8. Prognostic stromal gene signatures in breast cancer.
Winslow S; Leandersson K; Edsjö A; Larsson C
Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
[TBL] [Abstract][Full Text] [Related]
9. Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes.
Wu JM; Beck AH; Pate LL; Witten D; Zhu SX; Montgomery KD; Allison KH; van de Rijn M; West RB
Clin Cancer Res; 2011 Feb; 17(3):437-46. PubMed ID: 21098336
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
11. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients.
Román-Pérez E; Casbas-Hernández P; Pirone JR; Rein J; Carey LA; Lubet RA; Mani SA; Amos KD; Troester MA
Breast Cancer Res; 2012 Mar; 14(2):R51. PubMed ID: 22429463
[TBL] [Abstract][Full Text] [Related]
12. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
13. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients.
Rajski M; Zanetti-Dällenbach R; Vogel B; Herrmann R; Rochlitz C; Buess M
BMC Med; 2010 Jan; 8():1. PubMed ID: 20051100
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.
Planche A; Bacac M; Provero P; Fusco C; Delorenzi M; Stehle JC; Stamenkovic I
PLoS One; 2011; 6(5):e18640. PubMed ID: 21611158
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract][Full Text] [Related]
16. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract][Full Text] [Related]
17. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.
Giordano C; Chemi F; Panza S; Barone I; Bonofiglio D; Lanzino M; Cordella A; Campana A; Hashim A; Rizza P; Leggio A; Győrffy B; Simões BM; Clarke RB; Weisz A; Catalano S; Andò S
Oncotarget; 2016 Jan; 7(2):1262-75. PubMed ID: 26556856
[TBL] [Abstract][Full Text] [Related]
18. The macrophage colony-stimulating factor 1 response signature in breast carcinoma.
Beck AH; Espinosa I; Edris B; Li R; Montgomery K; Zhu S; Varma S; Marinelli RJ; van de Rijn M; West RB
Clin Cancer Res; 2009 Feb; 15(3):778-87. PubMed ID: 19188147
[TBL] [Abstract][Full Text] [Related]
19. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.
Triulzi T; Casalini P; Sandri M; Ratti M; Carcangiu ML; Colombo MP; Balsari A; Ménard S; Orlandi R; Tagliabue E
PLoS One; 2013; 8(2):e56761. PubMed ID: 23441215
[TBL] [Abstract][Full Text] [Related]
20. 3'-end sequencing for expression quantification (3SEQ) from archival tumor samples.
Beck AH; Weng Z; Witten DM; Zhu S; Foley JW; Lacroute P; Smith CL; Tibshirani R; van de Rijn M; Sidow A; West RB
PLoS One; 2010 Jan; 5(1):e8768. PubMed ID: 20098735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
